Related Experiment Video

Updated: May 21, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

miRNAs, a potential target in the treatment of Non-Small-Cell Lung Carcinomas

Marine Malleter1, Catherine Jacquot, Bénédicte Rousseau

  • 1Nantes University, Nantes Atlantique University, IICIMED/ERT-A0902, Cancer du Poumon et Cibles Moléculaires (CPCM), UFR Sciences Pharmaceutiques, Nantes, France.

Gene
|June 27, 2012
PubMed

Insights

New research explores microRNAs (miRNAs) in non-small cell lung cancer (NSCLC). Scientists identified hsa-miR-146b overexpression and potential regulatory roles for B2 ncRNA in NSCLC, offering novel therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) presents a significant public health challenge due to its resistance to current therapies.
  • MicroRNAs (miRNAs) are increasingly recognized for their roles in cancer development and progression.
  • The HEF1 gene and B2 large non-coding RNA (ncRNA), located at chromosome 6p24-25, are implicated in cell cycle functions and may interact.

Purpose of the Study:

  • To investigate the expression of specific miRNAs targeting the HEF1 gene in NSCLC cells.
  • To explore the potential regulatory role of B2 ncRNA in HEF1 expression and its implications in lung cancer carcinogenesis.
  • To identify novel therapeutic strategies for NSCLC treatment.

Main Methods:

  • Overexpression of HEF1 and B2 in vitro in NSCLC-N6 cells using the cytostatic molecule A190.
  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) to assess miRNA expression.
  • Bioinformatic analysis to identify potential B2 RNA structures interacting with HEF1.

Main Results:

  • Confirmed expression of known miRNAs that interact with HEF1 exons in NSCLC-N6 cells.
  • Highlighted significant overexpression of hsa-miR-146b in NSCLC-N6 cells.
  • Identified potentially expressed miRNAs originating from B2 ncRNA, suggesting a regulatory role in HEF1 expression.

Conclusions:

  • hsa-miR-146b and B2 ncRNA-derived miRNAs are expressed in NSCLC and may play a role in regulating HEF1.
  • These findings suggest potential innovative therapeutic targets for lung cancer treatment.
  • Further research into these miRNAs could lead to new strategies against NSCLC.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...